Skip to main content
Clinical Trials/NCT06212440
NCT06212440
Completed
Not Applicable

Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy : Expanded Access Clinical Study in 3 Arms

National Cancer Center, Korea2 sites in 1 country348 target enrollmentMay 4, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sentinel Lymph Node Biopsy
Sponsor
National Cancer Center, Korea
Enrollment
348
Locations
2
Primary Endpoint
Identification rate of sentinel lymph node
Status
Completed
Last Updated
last year

Overview

Brief Summary

This clinical trial aimed to confirm the effectiveness of sentinel lymph node surgery by determining the lymph node identification rate using multimodal sentinel lymph node marker methods in patients with advanced breast cancer undergoing neoadjuvant chemotherapy (NAC).

Detailed Description

After NAC, the sentinel lymph node (SLN) identification rate is lower, and it has a higher false-negative rate than that in early-stage breast cancer. As appropriate SLN surgery directly affects the treatment and prognosis of patients undergoing NAC, evaluation to identify SLN using various methods is necessary. This clinical trial aimed to confirm the effectiveness of sentinel lymph node surgery by determining the lymph node identification rate using multimodal sentinel lymph node marker methods in patients with advanced breast cancer undergoing neoadjuvant chemotherapy (NAC).

Registry
clinicaltrials.gov
Start Date
May 4, 2021
End Date
October 2, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Seeyoun Lee

Doctor, M.D., head of center for breast cancer

National Cancer Center, Korea

Eligibility Criteria

Inclusion Criteria

  • The patient with locally advanced breast cancer who achieved neoadjuvant chemotherapy
  • Confirmed operability with imaging study after neoadjuvant chemotherapy
  • Age over 20 years old
  • ECOG Performance status : 0-2
  • The patient with written informed consent form

Exclusion Criteria

  • The patient with previous ipsilateral breast cancer history
  • The patinet with previous ipsilateral axillary surgical procedure (e.g. excisional or incisional biopsy, axillary dissection)
  • The patient without neoadjuvant chemotherapy
  • Inoperable imaging study after neoadjuvant chemotherapy
  • Inflammatory breast cancer
  • Pregnant patient

Outcomes

Primary Outcomes

Identification rate of sentinel lymph node

Time Frame: during operation

Collection of data for detection rate of sentinel lymph node for each group following direct comparison between each arms.

Secondary Outcomes

  • Comparison of operation time for sentinel lymph node biopsy(during operation)

Study Sites (2)

Loading locations...

Similar Trials